First South Korean Report of 'Voice Changes' Adverse Event with Leclaza Combination Therapy
Vocal cord mucosa thickened in four patients
U.S. FDA also received 10 reports of "voice changes"
"Causality has not yet been established"
A case of vocal cord mucosal thickening that changed a patient's voice has been reported in South Korea for the first time in a patient treated with Yuhan Corporation's lung cancer drug Leclaza (ingredient: lazertinib).
Leclaza is a domestically developed anticancer drug that competes with Tagrisso (ingredient: osimertinib), the previous standard of care, in the global first-line lung cancer treatment market when used in combination with Johnson & Johnson's (J&J) Rybrevant (ingredient: amivantamab). Three of the four patients in the newly reported cases received this combination therapy.
According to medical professionals on the 28th, a research team at Seoul National University Bundang Hospital recently published these findings in the international journal Journal of Korean Medical Science (JKMS). The study was a case report documenting cases observed by medical staff during treatment. The team analyzed medical records for four lung cancer patients who developed voice changes or a new sensation of something being stuck in their throats while receiving Leclaza treatment.
Product image of Leclaza, Yuhan Corporation's lung cancer treatment. Yuhan Corporation.
View original imageEndoscopic examinations of the inside of the patients' vocal cords showed that mucous membranes in several areas, including both vocal cords, were swollen and thickened like growths. Their appearance differed from common vocal cord conditions caused by acid reflux or excessive voice use. None of the four patients smoked or drank alcohol, and none had a history of reflux disease. Most had been receiving treatment for two to three years.
The research team said this was the first reported case of such vocal cord abnormalities during Leclaza treatment. However, it said the small number of patients and the inability to rule out all other causes meant it could not conclude that the drugs were responsible. The team added that because three of the four patients had taken the two drugs together, it was difficult to determine whether Leclaza or Rybrevant had caused the effect.
The team speculated on the cause based on how the two drugs work. Leclaza and Rybrevant block signals from a protein called EGFR that promotes cancer cell growth. These signals are also involved in the formation of new skin and mucosal cells and in wound healing. This is why skin rashes and mouth inflammation are common with drugs in this class. The team suggested that the vocal cord mucosa may have been affected through the same mechanism. The combination therapy suppresses EGFR signals in two ways by using Leclaza, an oral drug, together with Rybrevant, an injectable drug.
Similar reports have also been submitted to the U.S. Food and Drug Administration (FDA). According to data from the FDA Adverse Event Reporting System (FAERS) through June 2026, 10 of the 709 reports related to Leclaza (1.4%) involved voice changes, vocal cord abnormalities, or similar issues. Seven of these cases involved patients receiving combination therapy, and two reports described a membrane forming between the vocal cords. For competing drug Tagrisso, made by AstraZeneca, voice changes, vocal cord abnormalities, or similar issues were reported in 80 of 32,522 total reports (0.25%); there were no reports of a membrane or growth forming on the vocal cords.
Leclaza, a domestically developed drug by Yuhan Corporation, was approved in South Korea in 2021. Yuhan transferred overseas rights to J&J in 2018, and J&J sells the drug in the United States under the brand name Lazcluze, in combination with Rybrevant. The combination therapy was approved by the FDA in August 2024.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The Leclaza-Rybrevant combination therapy competes with Tagrisso in the global first-line lung cancer treatment market. Tagrisso is a leading first-line treatment for EGFR-mutated non-small cell lung cancer and generated $7.25 billion in sales last year, equivalent to approximately 10 trillion won. In clinical trials, the Leclaza-Rybrevant combination reduced the risk of death by 25% compared with Tagrisso, and its three-year overall survival rate was 60%, higher than Tagrisso's 51%. However, a higher incidence of adverse reactions, including skin rashes, is considered a weakness.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.